Tested Applications
| Positive WB detected in | HL-60 cells, COLO 320 cells, human kidney tissue, human ovary cancer cells, rat pancreas tissue, human brain tissue, mouse liver tissue, U-251 cells, U-397 cells |
| Positive IP detected in | mouse heart tissue |
| Positive IHC detected in | mouse liver tissue, human placenta tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
| Positive IF/ICC detected in | HeLa cells |
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:1000-1:6000 |
| Immunoprecipitation (IP) | IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate |
| Immunohistochemistry (IHC) | IHC : 1:50-1:500 |
| Immunofluorescence (IF)/ICC | IF/ICC : 1:20-1:200 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
17311-1-AP targets ERLIN1 in WB, IHC, IF/ICC, IP, ELISA applications and shows reactivity with human, mouse, rat samples.
| Tested Reactivity | human, mouse, rat |
| Cited Reactivity | human, mouse |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen |
CatNo: Ag11279 Product name: Recombinant human ERLIN1 protein Source: e coli.-derived, PGEX-4T Tag: GST Domain: 29-346 aa of BC031791 Sequence: GHLAVYYRGGALLTSPSGPGYHIMLPFITTFRSVQTTLQTDEVKNVPCGTSGGVMIYIDRIEVVNMLAPYAVFDIVRNYTADYDKTLIFNKIHHELNQFCSAHTLQEVYIELFDQIDENLKQALQKDLNLMAPGLTIQAVRVTKPKIPEAIRRNFELMEAEKTKLLIAAQKQKVVEKEAETERKKAVIEAEKIAQVAKIRFQQKVMEKETEKRISEIEDAAFLAREKAKADAEYYAAHKYATSNKHKLTPEYLELKKYQAIASNSKIYFGSNIPNMFVDSSCALKYSDIRTGRESSLPSKEALEPSGENVIQNKESTG Predict reactive species |
| Full Name | ER lipid raft associated 1 |
| Calculated Molecular Weight | 346 aa, 39 kDa |
| Observed Molecular Weight | 39 kDa |
| GenBank Accession Number | BC031791 |
| Gene Symbol | ERLIN1 |
| Gene ID (NCBI) | 10613 |
| RRID | AB_2098590 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | O75477 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Protocols
| Product Specific Protocols | |
|---|---|
| IF protocol for ERLIN1 antibody 17311-1-AP | Download protocol |
| IHC protocol for ERLIN1 antibody 17311-1-AP | Download protocol |
| IP protocol for ERLIN1 antibody 17311-1-AP | Download protocol |
| WB protocol for ERLIN1 antibody 17311-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
What published studies show
The Anti-ERLIN1 antibody (Cat# 17311-1-AP) has 8 total citations published in Cell, Molecular Cell, Experimental Neurology, Frontiers in Molecular Biosciences, PLoS Genetics, and eLife. Associated research fields include ER-associated protein quality control, apoptosis, membrane microdomain assembly, neuronal oxidative stress and traumatic brain injury, rheumatoid arthritis and lung adenocarcinoma prognosis, non-alcoholic fatty liver disease, and antigen cross-presentation in dendritic cells.
| Species | Application | Title |
|---|---|---|
Cell BOK Is a Non-canonical BCL-2 Family Effector of Apoptosis Regulated by ER-Associated Degradation. | ||
Mol Cell Quality Control of ER Membrane Proteins by the RNF185/Membralin Ubiquitin Ligase Complex | ||
Mol Cell Quality Control of ER Membrane Proteins by the RNF185/Membralin Ubiquitin Ligase Complex. | ||
Mol Cell The Erlin1/2 complex is a dynamic scaffold for membrane microdomain assembly on the endoplasmic reticulum. | ||
Exp Neurol circCrebrf modulates the miR-3562/ERLIN1 axis to suppress neuronal oxidative stress and apoptosis following traumatic brain injury. | ||
Front Mol Biosci Construction of shared gene signature between rheumatoid arthritis and lung adenocarcinoma helps to predict the prognosis and tumor microenvironment of the LUAD patients |
